Squarepoint’s Anavex Life Sciences AVXL Stock Holding History

Squarepoint’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-278,800	Closed	-$2.58M	–	3221
2022 Q4	$2.58M	Buy	+278,800	New	+$2.98M	0.01%	1214

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Squarepoint's AVXL Position: Q1 2026 in Review

Squarepoint sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 56,363 shares — an estimated $201K sold.

Squarepoint first reported a position in AVXL in Q1 2016 and held it in 20 quarters. The position peaked at $1.09M in Q3 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

Squarepoint reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 56,363 Anavex Life Sciences shares in Q1 2026, an estimated $201K.
Squarepoint first reported a position in Anavex Life Sciences in Q1 2016 and held it in 20 quarters.
Squarepoint's Anavex Life Sciences position peaked at $1.09M in Q3 2021.
190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.